CA
CABA
Cabaletta Bio, Inc.
$3.01
0.00%
$490.8M
No data for this timeframe.
Vol
Market Cap$490.8M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (81%)
Inst. Holders50 funds
Inst. Value$110.4M
Inst. Activity5 buys / 3 sells
Reddit Sentiment75° Bullish
SEC Reports12
Press Releases1
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001759138·Prev Close $3.01
Recent Activity
Jun 11, 2026
SEC
{
"summary": "An institutional cluster for Cabaletta Bio (CABA) from Q3 2024 reveals heavy distribution: Alkeon Capita
INST-CLUSTER — Impact 5/10
Jun 9, 2026
Insider
Brun Scott C. was granted 22,000 shares
Director
Jun 9, 2026
Insider
Bollard Catherine was granted 22,000 shares
Director
Jun 9, 2026
Insider
HENRIQUES RICHARD C JR was granted 22,000 shares
Director
Jun 5, 2026
SEC
Cabaletta Bio presented updated Phase 1/2 clinical data for rese-cel across multiple autoimmune indications at EULAR 202
8-K — Impact 7/10
Jun 1, 2026
SEC
Cabaletta Bio's board withdrew Proposal 3 (amendment to the 2019 Stock Option and Incentive Plan) from the June 9, 2026
DEFA14A — Impact 3/10
Inst.
MARSHALL WACE, LLP — DOUBLED
2,179,818 shares ($5.9M)
Inst.
RENAISSANCE TECHNOLOGIES LLC — ADD
2,036,663 shares ($5.5M)
Price Targets
$13.38
+344.4% upside
Strong Buy
Current $3.01
Low $4.00
Median $13.50
High $30.00
8 analysts
$4.00
$30.00
Analyst Ratings
6Strong Buy
7Buy
3Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 15, 2026 | Wells Fargo | MAINTAIN | Equal-Weight → Equal-Weight |
| May 4, 2026 | Cantor Fitzgerald | REITERATE | Overweight → Overweight |
| Mar 24, 2026 | Morgan Stanley | MAINTAIN | Overweight → Overweight |
| Mar 24, 2026 | Guggenheim | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.34 ▲ +21.8% | $-0.41 — $-0.26 | 53% YoY | 5 |
| Next Q | $-0.31 ▲ +17.2% | $-0.42 — $-0.20 | 28% YoY | 5 |
| Current FY | $-1.34 ▲ +12.9% | $-1.64 — $-1.00 | 36% YoY | 5 |
| Next FY | $-1.42 ▼ -1.1% | $-2.63 — $-0.80 | -6% YoY | 5 |
Latest Reports
NEUTRAL
INST-CLUSTER
5/10
{
"summary": "An institutional cluster for Cabaletta Bio (CABA) from Q3 2024 reveals heavy distribution: Alkeon Capita
Jun 11, 2026
BULLISH
8-K
7/10
Cabaletta Bio presented updated Phase 1/2 clinical data for rese-cel across multiple autoimmune indications at EULAR 202
Jun 5, 2026
NEUTRAL
Press
5/10
Cabaletta Bio reported Q4 and full-year 2025 financial results, highlighted by increased R&D spending and a cash positio
Mar 23, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| JENNISON ASSOCIATES LLC | $24.1M | ADD |
| ADAGE CAPITAL PARTNERS GP, | $23.8M | DOUBLED |
| VANGUARD CAPITAL MANAGEMENT LLC | $10.8M | — |
| TWO SIGMA INVESTMENTS, LP | $6.7M | DOUBLED |
| BlackRock, Inc. | $6.4M | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 9, 2026 | Brun Scott | A | $0.00 |
| Jun 9, 2026 | Bollard Catherine | A | $0.00 |
| Jun 9, 2026 | HENRIQUES RICHARD | A | $0.00 |
| Jun 9, 2026 | Simon Mark | A | $0.00 |
| Jun 9, 2026 | Tomasello Shawn | A | $0.00 |
Reddit Sentiment
75°
Bullish
Bearish
Neutral
Bullish
50 institutional holders with $110.4M total value (41,534,873 shares) as of 2026-Q1. Top holders: JENNISON, ADAGE, VANGUARD. Net buying activity: 5 institutions added/increased vs 3 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | JENNISON ASSOCIATES LLC | 8,970,578 | $24.1M | 21.9% | ADD +41.2% |
| 2 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 8,829,758 | $23.8M | 21.5% | DOUBLED +142.9% |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 4,028,991 | $10.8M | 9.8% | — |
| 4 | TWO SIGMA INVESTMENTS, LP | 2,497,917 | $6.7M | 6.1% | DOUBLED +291.1% |
| 5 | BlackRock, Inc. | 2,373,003 | $6.4M | 5.8% | ADD +43.7% |
| 6 | MARSHALL WACE, LLP | 2,179,818 | $5.9M | 5.3% | DOUBLED +127.3% |
| 7 | RENAISSANCE TECHNOLOGIES LLC | 2,036,663 | $5.5M | 5.0% | ADD +33.8% |
| 8 | MORGAN STANLEY | 1,408,152 | $3.8M | 3.4% | — |
| 9 | Woodline Partners LP | 1,250,242 | $3.4M | 3.0% | TRIM -41.5% |
| 10 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1,078,900 | $2.9M | 2.6% | — |
| 11 | GOLDMAN SACHS GROUP INC | 783,220 | $2.1M | 1.9% | — |
| 12 | DIMENSIONAL FUND ADVISORS LP | 740,648 | $2.0M | 1.8% | ADD +63.8% |
| 13 | SCHRODER INVESTMENT MANAGEMENT GROUP | 756,637 | $1.9M | 1.7% | — |
| 14 | VANGUARD FIDUCIARY TRUST CO | 570,191 | $1.5M | 1.4% | — |
| 15 | CITADEL ADVISORS LLC | 478,600 | $1.3M | 1.2% | TRIM -58.2% |
| 16 | STATE STREET CORP | 469,978 | $1.3M | 1.1% | ADD +72.9% |
| 17 | BANK OF AMERICA CORP /DE/ | 269,257 | $724.3K | 0.7% | DOUBLED +1770.9% |
| 18 | WELLINGTON MANAGEMENT GROUP LLP | 247,659 | $666.2K | 0.6% | — |
| 19 | Point72 Asset Management, L.P. | 246,615 | $663.4K | 0.6% | DOUBLED +335.3% |
| 20 | GOLDMAN SACHS GROUP INC | 246,500 | $663.1K | 0.6% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MARSHALL WACE, LLP | DOUBLED | 959,076 | 2,179,818 | +127.3% | $5.9M | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 1,522,583 | 2,036,663 | +33.8% | $5.5M | 2026-Q1 |
| DIMENSIONAL FUND ADVISORS LP | ADD | 452,039 | 740,648 | +63.8% | $2.0M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 14,392 | 269,257 | +1770.9% | $724.3K | 2026-Q1 |
| Point72 Asset Management, L.P. | DOUBLED | 56,648 | 246,615 | +335.3% | $663.4K | 2026-Q1 |
| OMERS ADMINISTRATION Corp | TRIM | 95,400 | 54,100 | -43.3% | $145.5K | 2026-Q1 |
| BALYASNY ASSET MANAGEMENT L.P. | NEAR_EXIT | 51,552 | 11,154 | -78.4% | $30.0K | 2026-Q1 |
| PRICE T ROWE ASSOCIATES INC /MD/ | TRIM | 1,093,959 | 442,277 | -59.6% | $1.2K | 2026-Q1 |
| BlackRock, Inc. | ADD | 1,620,872 | 2,328,470 | +43.7% | $5.1M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 470,475 | 1,839,799 | +291.1% | $4.0M | 2025-Q4 |
| Woodline Partners LP | TRIM | 2,135,348 | 1,250,242 | -41.5% | $2.7M | 2025-Q4 |
| MARSHALL WACE, LLP | TRIM | 1,326,043 | 959,076 | -27.7% | $2.1M | 2025-Q4 |
| Invesco Ltd. | ADD | 122,800 | 189,195 | +54.1% | $414.3K | 2025-Q4 |
| FRED ALGER MANAGEMENT, LLC | TRIM | 59,813 | 28,021 | -53.2% | $61.4K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 268,058 | 14,392 | -94.6% | $31.5K | 2025-Q4 |
| PNC FINANCIAL SERVICES GROUP, INC. | DOUBLED | 600 | 4,600 | +666.7% | $10.1K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | TRIM | 3,000 | 2,000 | -33.3% | $4.4K | 2025-Q4 |
| JENNISON ASSOCIATES LLC | ADD | 6,020,167 | 8,497,537 | +41.2% | $19.9M | 2025-Q3 |
| Woodline Partners LP | ADD | 1,218,464 | 2,135,348 | +75.2% | $5.0M | 2025-Q3 |
| BlackRock, Inc. | ADD | 970,601 | 1,620,872 | +67.0% | $3.8M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 126,100 | 1,339,423 | +962.2% | $3.1M | 2025-Q3 |
| MARSHALL WACE, LLP | DOUBLED | 190,957 | 1,326,043 | +594.4% | $3.1M | 2025-Q3 |
| Alyeska Investment Group, L.P. | TRIM | 4,800,000 | 1,300,000 | -72.9% | $3.0M | 2025-Q3 |
| CITADEL ADVISORS LLC | TRIM | 1,687,980 | 705,465 | -58.2% | $1.7M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | ADD | 252,357 | 470,475 | +86.4% | $1.1M | 2025-Q3 |
11 unique insiders with 11 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 9, 2026 | Brun Scott C. | Director | AWARD | 22,000 | — | — |
| Jun 9, 2026 | Bollard Catherine | Director | AWARD | 22,000 | — | — |
| Jun 9, 2026 | HENRIQUES RICHARD C JR | Director | AWARD | 22,000 | — | — |
| Jun 9, 2026 | Simon Mark | Director | AWARD | 22,000 | — | — |
| Jun 9, 2026 | Tomasello Shawn | Director | AWARD | 22,000 | — | — |
| Mar 2, 2026 | Chang David J. | Chief Medical Officer | AWARD | 225,000 | — | — |
| Mar 2, 2026 | Nichtberger Steven | President & CEO | AWARD | 674,000 | — | — |
| Mar 2, 2026 | Marda Anup | Chief Financial Officer | AWARD | 225,000 | — | — |
| Mar 2, 2026 | Das Arun | Chief Business Officer | AWARD | 175,000 | — | — |
| Mar 2, 2026 | Gerard Michael | General Counsel | AWARD | 175,000 | — | — |
| Mar 2, 2026 | Binder Gwendolyn | President, Science & Tech. | AWARD | 225,000 | — | — |
12 SEC filing reports analyzed. Sentiment: 4 bullish, 3 bearish, 0 mixed, 5 neutral. Avg impact: 5.3/10.
NEUTRAL
INST-CLUSTER
5/10
{
"summary": "An institutional cluster for Cabaletta Bio (CABA) from Q3 2024 reveals heavy distrib
Jun 11, 2026
BULLISH
8-K
7/10
Cabaletta Bio presented updated Phase 1/2 clinical data for rese-cel across multiple autoimmune indi
Jun 5, 2026
NEUTRAL
DEFA14A
3/10
Cabaletta Bio's board withdrew Proposal 3 (amendment to the 2019 Stock Option and Incentive Plan) fr
Jun 1, 2026
BULLISH
8-K
7/10
Cabaletta Bio presented new clinical data at ASGCT 2026 showing that 2 of 4 refractory pemphigus vul
May 14, 2026
BEARISH
8-K
6/10
Cabaletta Bio reported Q1 2026 net loss of $43.5M (EPS -$0.39, beating consensus of -$0.41 by ~5%) w
May 14, 2026
NEUTRAL
PRESS-RELEASE
4/10
Cabaletta Bio reported Q1 2026 EPS of -$0.40, a 3.1% miss vs consensus of -$0.39, with no revenue. T
May 14, 2026
BEARISH
8-K
7/10
Cabaletta Bio priced a $150M underwritten offering of 51.7M shares at $2.90/share, representing ~51%
May 4, 2026
BEARISH
424B5
7/10
Cabaletta Bio is selling 51,725,000 shares of common stock at $2.90 per share in a dilutive follow-o
May 4, 2026
NEUTRAL
8-K
3/10
Cabaletta Bio announced it will present new clinical and translational data from 4 refractory patien
May 4, 2026
NEUTRAL
DEFA14A
2/10
Cabaletta Bio files additional proxy materials for its 2026 annual meeting. The board recommends vot
Apr 28, 2026
BULLISH
8-K
7/10
Cabaletta Bio updated its corporate presentation with clinical data showing positive safety and effi
Apr 20, 2026
BULLISH
INST-CLUSTER
6/10
Three major passive institutions — Morgan Stanley, Wells Fargo, and UBS — significantly increased th
Feb 28, 2026
Current analyst consensus: Strong Buy (81% buy). Based on 16 analysts: 6 strong buy, 7 buy, 3 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$13.38 mean target
+344.4% upside
Strong Buy (1.50)
$4.00 Low
$30.00 High
| Metric | Value |
|---|---|
| Current Price | $3.01 |
| Target Low | $4.00 |
| Target Mean | $13.38 |
| Target Median | $13.50 |
| Target High | $30.00 |
| # Analysts | 8 |
| Recommendation | Strong Buy (1.50) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.34 | $-0.41 | $-0.26 | 53.1% | +21.8% | — | $0.0B | 0.0% | 5 |
| Next Q 2026-09-30 |
$-0.31 | $-0.42 | $-0.20 | 28.4% | +17.2% | — | $0.0B | 0.0% | 5 |
| Current FY 2026-12-31 |
$-1.34 | $-1.64 | $-1.00 | 36.3% | +12.9% | 1↑ 0↓ | $0.0B | 0.0% | 5 |
| Next FY 2027-12-31 |
$-1.42 | $-2.63 | $-0.80 | -6.1% | -1.1% | 1↑ 0↓ | $0.0B | 0.0% | 5 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.343 | |
| 7d ago | $-0.345 | +0.002 |
| 30d ago | $-0.438 | +0.095 |
| 60d ago | $-0.448 | +0.105 |
| 90d ago | $-0.432 | +0.090 |
4 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 15, 2026 | Wells Fargo | MAINTAIN | Equal-Weight | Equal-Weight |
| May 4, 2026 | Cantor Fitzgerald | REITERATE | Overweight | Overweight |
| Mar 24, 2026 | Morgan Stanley | MAINTAIN | Overweight | Overweight |
| Mar 24, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 6 | 7 | 3 | 0 | 0 | 81% | |
| May 1, 2026 | 6 | 7 | 3 | 0 | 0 | 81% | |
| Apr 1, 2026 | 6 | 7 | 3 | 0 | 0 | 81% | |
| Mar 1, 2026 | 6 | 7 | 3 | 0 | 0 | 81% | |
| Feb 1, 2026 | 6 | 7 | 3 | 0 | 0 | 81% | |
| Jan 1, 2026 | 6 | 7 | 3 | 0 | 0 | 81% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
75°
Bullish
Bearish
Neutral
Bullish
4 mentions
4 bullish
0 bearish
4 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 22, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 22, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 1, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 1, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
Jun 3, 2026
other
Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress
<p align="center"><em>83% of dermatomyositis patients in the Phase 1/2 RESET-Myositis study would have met the registrational primary endpoint; all th
May 19, 2026
short_volume
Short Volume: CABA — 56.3% short (0.7M / 1.3M)
Short: 717,564 | Exempt: 6,604 | TRF Vol: 1,274,697 | Short Ratio: 56.3% | Off-exchange volume (dark pool + OTC)
May 18, 2026
short_volume
Short Volume: CABA — 57.3% short (0.6M / 1.1M)
Short: 622,563 | Exempt: 13,596 | TRF Vol: 1,087,053 | Short Ratio: 57.3% | Off-exchange volume (dark pool + OTC)
May 15, 2026
short_volume
Short Volume: CABA — 60.6% short (0.8M / 1.3M)
Short: 783,402 | Exempt: 0 | TRF Vol: 1,293,650 | Short Ratio: 60.6% | Off-exchange volume (dark pool + OTC)
May 14, 2026
earnings
Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update
<p align="center"><em>Preconditioning-free (PC-free) 6-to-9-month clinical data with a single infusion of the lowest dose of rese-cel in the RESET-PV<
May 13, 2026
earnings_calendar
CABA Q1 2026 Earnings Before Market Open — 2026-05-13
May 4, 2026
other
Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering
<p>PHILADELPHIA, May 04, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology
Apr 30, 2026
short_volume
Short Volume: CABA — 56.3% short (0.4M / 0.7M)
Short: 407,801 | Exempt: 0 | TRF Vol: 724,362 | Short Ratio: 56.3% | Off-exchange volume (dark pool + OTC)
Apr 27, 2026
routine
Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting
<p>PHILADELPHIA, April 27, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on devel
Apr 23, 2026
short_volume
Short Volume: CABA — 70.8% short (0.5M / 0.7M)
Short: 477,373 | Exempt: 400 | TRF Vol: 673,898 | Short Ratio: 70.8% | Off-exchange volume (dark pool + OTC)
Apr 20, 2026
short_interest
FTD: CABA — 179,500 shares ($0.6M) failed to deliver
Settlement: 20260420, Price: $3.44, FTD Value: $617,480, CABALETTA BIO INC COM
Apr 10, 2026
short_volume
Short Volume: CABA — 58.4% short (0.4M / 0.6M)
Short: 363,763 | Exempt: 1,400 | TRF Vol: 622,514 | Short Ratio: 58.4% | Off-exchange volume (dark pool + OTC)
Apr 8, 2026
short_volume
Short Volume: CABA — 65.6% short (0.4M / 0.7M)
Short: 441,979 | Exempt: 108 | TRF Vol: 674,036 | Short Ratio: 65.6% | Off-exchange volume (dark pool + OTC)
Mar 30, 2026
earnings_calendar
CABA Q4 2025 Earnings After Market Close — 2026-03-30
Mar 27, 2026
short_volume
Short Volume: CABA — 60.2% short (0.9M / 1.5M)
Short: 884,999 | Exempt: 7,251 | TRF Vol: 1,470,674 | Short Ratio: 60.2% | Off-exchange volume (dark pool + OTC)